Prediction and evaluation of high-risk patients with primary biliary cholangitis receiving ursodeoxycholic acid therapy: an early criterion

BACKGROUND AND AIMS: Current treatment guidelines recommend ursodeoxycholic acid (UDCA) as the first-line treatment for new-diagnosed primary biliary cholangitis (PBC) patients. However, up to 40% patients are insensitive to UDCA monotherapy, and evaluation of UDCA response at 12 months may result i...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Chunmei, Guo, Guanya, Li, Bo, Zheng, Linhua, Sun, Ruiqing, Wang, Xiufang, Deng, Juan, Jia, Gui, Zhou, Xia, Cui, Lina, Guo, Changcun, Zhou, Xinmin, Leung, Patrick S. C., Gershwin, M. Eric, Shang, Yulong, Han, Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer India 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9895005/
https://www.ncbi.nlm.nih.gov/pubmed/36309918
http://dx.doi.org/10.1007/s12072-022-10431-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9895005/
https://www.ncbi.nlm.nih.gov/pubmed/36309918
http://dx.doi.org/10.1007/s12072-022-10431-7

Ejemplares similares